CA2188871C - Methode pour le traitement du psoriasis - Google Patents
Methode pour le traitement du psoriasis Download PDFInfo
- Publication number
- CA2188871C CA2188871C CA002188871A CA2188871A CA2188871C CA 2188871 C CA2188871 C CA 2188871C CA 002188871 A CA002188871 A CA 002188871A CA 2188871 A CA2188871 A CA 2188871A CA 2188871 C CA2188871 C CA 2188871C
- Authority
- CA
- Canada
- Prior art keywords
- interleukin
- use according
- psoriasis
- units
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 52
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 102000000588 Interleukin-2 Human genes 0.000 claims description 51
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 102000055277 human IL2 Human genes 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 238000011285 therapeutic regimen Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 13
- 230000001185 psoriatic effect Effects 0.000 abstract description 10
- 206010048768 Dermatosis Diseases 0.000 abstract description 7
- 208000017520 skin disease Diseases 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000004526 exfoliative dermatitis Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010065874 Psoriatic conditions Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un procédé thérapeutique permettant de traiter un être humain souffrant de psoriasis et qui consiste à administrer au sujet une quantité efficace d'IL-2 inhibant une dermatose psoriasique, et un excipient pharmaceutiquement acceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1993/008953 WO1995008340A1 (fr) | 1993-09-21 | 1993-09-21 | Procede de traitement du psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2188871A1 CA2188871A1 (fr) | 1995-03-30 |
| CA2188871C true CA2188871C (fr) | 2001-01-23 |
Family
ID=22236983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002188871A Expired - Fee Related CA2188871C (fr) | 1993-09-21 | 1993-09-21 | Methode pour le traitement du psoriasis |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5134693A (fr) |
| CA (1) | CA2188871C (fr) |
| WO (1) | WO1995008340A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536905A (zh) * | 2013-10-28 | 2014-01-29 | 中国医学科学院基础医学研究所 | 白介素-2在制备银屑病药物中的应用 |
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3538548A4 (fr) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | Variants d'il-2 pour le traitement de maladies auto-immunes |
-
1993
- 1993-09-21 WO PCT/US1993/008953 patent/WO1995008340A1/fr not_active Ceased
- 1993-09-21 AU AU51346/93A patent/AU5134693A/en not_active Abandoned
- 1993-09-21 CA CA002188871A patent/CA2188871C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995008340A1 (fr) | 1995-03-30 |
| CA2188871A1 (fr) | 1995-03-30 |
| AU5134693A (en) | 1995-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5449522A (en) | Pharmaceutical composition for immunoenhancement therapy | |
| Lee et al. | Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. | |
| US5128126A (en) | Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions | |
| US6143717A (en) | Pharmaceutical composition and method for immunoenhancement therapy | |
| CN1094642A (zh) | 治疗组合物 | |
| US5466447A (en) | Method for treating psoriasis | |
| AU661979B2 (en) | Use of IL-4 to treat solid tumors | |
| US5582822A (en) | Treatment of leukemia using interleukin 2 | |
| US5178855A (en) | Treatment of luekocyte dysfunction with GM-CSF | |
| EP0225759B1 (fr) | Compositions d'interféron | |
| CA2188871C (fr) | Methode pour le traitement du psoriasis | |
| EP0804227B1 (fr) | Utilisation de dimere de lysozyme pour traiter le cancer | |
| JP3266248B2 (ja) | 傷害を処置するための方法及び組成物 | |
| Larionov | Some biological and clinical results from the investigations of the chloroethylamines as anti-tumour drugs | |
| JP2784401B2 (ja) | 慢性骨髄性白血病の治療方法 | |
| Barbaro et al. | Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: a randomized, controlled clinical study | |
| US5211947A (en) | Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor | |
| Bui et al. | Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: effects on blood lymphocyte population in guinea pigs | |
| JP2008031179A (ja) | β−インターフェロンを使用して再狭窄を治療する方法 | |
| US5871725A (en) | Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
| EP0377823A2 (fr) | Utilisation de TNF pour l'obtention d'un médicament destiné au traitement du psoriasis | |
| CA2638985C (fr) | Agent therapeutique contenant de l'interferon .omega. felin pour le traitement de la dermatite atopique feline | |
| Nakano et al. | Accelerated recovery of antigen-presenting cell activity by the administration of interleukin 1α in 5-fluorouracil-treated mice | |
| JPH0618780B2 (ja) | 骨髄性白血病抑制剤 | |
| KR20010032511A (ko) | 조혈 간세포를 이동시키는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |